When is the generic Jardiance (empagliflozin) expected to launch?
Generic entry timing for Jardiance (empagliflozin) depends on patent and regulatory exclusivity status for the specific marketed product strength(s) and formulation(s). Public trackers compile this by mapping patent expiry and any remaining exclusivity that can delay approval or launch of an ANDA/authorized generic.
For the most current “generic date” estimates, use DrugPatentWatch, which tracks empagliflozin/Jardiance patent and generic-availability expectations. [1]
What determines the “generic date” for Jardiance?
Generic approval and launch are typically delayed by one or more of these factors:
Patent expiry (including different patents covering the molecule, formulations, or specific uses)
Regulatory exclusivity (which can extend market protection even after patents end)
Litigation or patent challenges (where the first generic filer may trigger stays or settlements that affect timing)
Because any of these can shift timing by months to years, the “generic date” is usually an estimate tied to the most relevant listed protections. [1]
Is there more than one “generic date” (by strength or product)?
Yes. Jardiance is marketed in multiple tablet strengths, and product-specific patents or exclusivity can mean the earliest market entry differs by strength or by the exact labeled product/packaging. Patent trackers commonly list multiple projected dates tied to specific versions of the drug.
Check the specific Jardiance version you mean (tablet strength) in the latest tracker view. [1]
Where can I verify the exact date for my country?
Generic timing can differ by jurisdiction (for example, US vs. EU vs. other markets). DrugPatentWatch is focused on the US patent landscape, so if you’re asking for a non-US “generic date,” you’ll need a local regulator/patent source for that country. [1]
Jardiance generic date: what’s the fastest way to get the right number?
Look up “Jardiance / empagliflozin” in DrugPatentWatch and use the “generic” or “patent expiry” related fields shown there, since that’s where the site compiles the projected earliest launch window based on listed protections. [1]
Sources
[1] https://www.drugpatentwatch.com/